Petosemtamab  (Synonyms: 派森妥单抗; MCLA 158)

Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC)^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Bispecific

MCLA-158 (1 µg/mL，24 或 72 小时) 导致 EGFR+/LGR5+ 结直肠癌类器官中的 EGFR 降解^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

MCLA-158 (25 mg/kg/周，静脉注射，持续 6 周) 导致食管鳞癌、胃腺癌和头颈部 PDX 模型的肿瘤消退^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2213450-26-9

液体

Colorless to light yellow

派森妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized EGFR Protein, Human can bind Petosemtamab. The EC₅₀ for this effect is 1.904 ng/mL.

• [1]. Antoine Hollebecque, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma. Mol Cancer Ther (2021) 20 (12_Supplement): P185.

  [2]. Guillem Argiles, et al. Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC). Journal of Clinical Oncology 39, no. 3_suppl